Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... A Kaiser Family Foundation survey from 2022 ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Regarding the 2024-2025 Pfizer-BioNTech COVID-19 vaccine ... The lawmaker has served in the Senate since 2011 and was most ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... during the coming 2022/23 flu season in the northern hemisphere.

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

Total reported deaths last January were 29. There were 16 fatalities in February, 12 in March, 3 in April, 6 in May, 2 in ...